After years of stagnation in the search for a cure for Alzheimer’s — or at least breakthroughs — 2024 brought several ...

The era of targeting these proteins at an early stage to minimise risk of Alzheimer’s progressing has started. The prospect ...

Background Cardiac amyloidosis (CA) is an underdiagnosed, progressive and lethal disease. Machine learning applied to common ...

This review provides an overview of Alzheimer’s disease (AD), discussing its complex pathophysiology, risk factors, and ...

Microglia have been revealed to first help spread Alzheimer’s disease pathology across the brain and then activate to limit ...

A recent study published in Neurology explored whether high doses of nicotinamide, a derivative of vitamin B3, could reduce a ...

FOX 9 caught up with a Minnesota woman undergoing a new Alzheimer’s treatment which is showing promise in slowing cognitive ...

The brain's immune cells, or microglia (light blue/purple) are shown interacting with amyloid plaques (red) — harmful protein ...

Tolcapone is under clinical development by Corino Therapeutics and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs for Amyloidosis have a 72% phase transition success ...

Birtamimab is under clinical development by Prothena Corp and currently in Phase III for Primary Systemic Amyloidosis.

Plasma p-tau217 immunoassay offers accurate detection of Alzheimer’s disease pathology, supporting early diagnosis and ...